Nature's Bioceuticals Consummates Purchase of Novel Weight Loss Formula

Tallahassee, FL 12/1/11 (StreetBeat) --Nature's Bioceuticals, a wholly owned subsidiary of Mistral Ventures Inc. (MILV.pk) announced that it has executed the closing document and consummated the purchase of the weight loss formula.

According to government data, 66% of the 229.5 million American adults are now overweight, or 151 million people, of which 71 million are considered obese. These are the people who are in greater and more immediate danger of developing obesity-related health complications such as heart attacks or diabetes. The larger group of 158 million overweight Americans constitutes the share, for whom their overweight condition is not life threatening; i.e. they're concerned with cosmetic weight loss to help them look and feel better.

According to surveys of American dieting habits performed by the Calorie Control Council, there are 72 million Americans on some kind of diet program. Male – 40% (28.8 million) Female – 60% (43.2 million). Market data projects the total 2010 U.S. weight loss market at $68.7 billion . The recession and the possibility of a double dip recession, has, and may, continue to hurt discretionary income and enrollments in structured programs. Dieters will continue to shift to less costly retail and do-it-yourself options such as: meal replacements, OTC diet pills, mail order plans, diet websites, and fad diet books.

Robert deZanger, CEO of Natures Bioceuticals, reiterates, "We are pleased to add the weight loss formula to our line of natural medicines. This very special formula will provide people a proven product that will help them lose weight. Our formula contains a proprietary blend of natural herbs that has caused weight loss in all people who have tried it. The formula simply curbs the appetite and speeds up the metabolism of those who take it. There is no jittery feeling associated with the product. People who take the formula notice no change in the way they feel. They simply are not as hungry and lose weight. There are many weight loss products on the market and the competition is fierce. We anticipate competition from at least one and probably several new prescription diet drugs that are likely to be approved for sale in the U.S. However, there is an ever increasing trend of people seeking natural remedies as the facts about the dangers of many prescription drugs come to light. We feel that we have a special product that will be well received and take off as people realize that it works. Further, management feels that the ban by the FDA of products with Ephedra and the negative press on other products containing similar 'stimulants' have left many people desperate to lose weight searching for an alternative. Obviously this is a huge market and capturing a small percentage can generate substantial profits for the company."

StreetBeat Disclaimer

Distributed by Viestly

Big Volume Today for Mistral Ventures (PINK:MILV)

Shawshank, VA 11/2/2011 (StreetBeat) – I Nature's Bioceuticals, a wholly owned subsidiary of Mistral Ventures Inc. (PINK:MILV) announced yesterday, in a press release, that it will purchase the exclusive rights to a formula that was developed to restore proper kidney function in people with chronic kidney disease (CKD).

Chronic kidney disease is a growing health problem in the United States. A report by the Centers for Disease Control (CDC) determined that 16.8% of all adults above the age of 20 years have chronic kidney disease. Thus, one in six individuals has kidney disease. By disease stage, the prevalence is as follows: stage 1, 3.1%; stage 2, 4.1%; stage 3, 7.6%; stage 4; and 5, 0.5%. There are over 500,000 persons on dialysis or who have received kidney transplants. The prevalence of chronic kidney disease has increased by 16% from the previous decade. The increasing incidence of diabetes mellitus, hypertension (high blood pressure), obesity, and an aging population have contributed to this increase in kidney disease.

Kidney disease raises the risk of early death, heart attack, stroke, and high blood pressure. CKD causes anemia, bone disease and malnutrition and can lead to kidney failure, which requires ongoing dialysis or a kidney transplant to maintain life. According to the National Institute of Health's U.S. Renal Data System, over 100,000 Americans started dialysis in 2005 while a total of over 485,000 received ongoing dialysis treatment or a kidney transplant, at a cost of $32 billion. The NIH estimates that by 2020 nearly 785,000 people will be receiving treatment for kidney failure, costing an estimated $53.6 billion. The healthcare costs for one person needing dialysis are between $150,000 – $200,000 per year, with annual global dialysis costs exceeding $1 trillion this decade.

Robert deZanger, CEO of Natures Bioceuticals stated "We are confident that this product will make a meaningful contribution to one of the most overlooked diseases known to man. The problem is most people with CKD aren't even aware they have the disease. Studies show that 4 out of 5 people with advanced CKD (i.e. loss of over 50% of kidney function) do not know they have the disease. Unless tested, diagnosed and dialysis or a transplant is available, many of these people only become unwell after severe kidney failure, when death is imminent. People who have taken our formula have shown substantial increases in kidney function in very short time frames. One positive side effect that has been noted is that the product seems to also shrink enlarged prostrate glands. This could be a second market for the product. Obviously, this product should create substantial revenues for the company and we are excited about the possibilities. Capturing just 0.5% of the market could produce revenues in excess of $100,000,000.00 and with the correct marketing program we believe it could be possible to capture a greater percent of the market within the first few years. Upon closing of the purchase we intend to file the patent documents and then immediately proceed with formal clinical trials to document the amazing results obtained to this point."

PennyPayDay Disclaimer

Distributed by Viestly